CEP-701 (Lestaurtinib)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for CEP-701 (Lestaurtinib), covering 2014-11-26 to 2015-10-08. Get the full timeline:
Most recent: Clinical Trial Update: Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis [Phase 2]